Novartis stock holds firm as pipeline focus follows Q2 2026 earnings beat

Novartis AG (ISIN CH0012005267) stock remains supported by solid recent financial results, with investors continuing to weigh the pharmaceuticals group’s Q2 2026 earnings beat and updated guidance for full year 2026. According to the company’s Q2 2026 results published on 16 July 2026, Novartis reported higher core operating income and reaffirmed its strategic focus on innovative medicines, underpinning interest in Novartis stock on SIX Swiss Exchange.

Core operating income rises in Q2 2026

In its Q2 2026 earnings release dated 16 July 2026, Novartis reported group net sales of around $12.0 billion for the quarter, reflecting mid single digit growth compared to approximately $11.4 billion in Q2 2025 according to the company’s investor materials. The sales performance was driven by key innovative medicines across immunology, oncology and cardiovascular segments, reinforcing Novartis’ pivot toward higher margin therapies.

According to the same Q2 2026 presentation, Novartis recorded core operating income of roughly $4.0 billion for Q2 2026, up from about $3.6 billion in Q2 2025. This represents growth of around 11%, highlighting improved operational leverage and cost discipline alongside ongoing investment in the research pipeline. Management pointed to productivity initiatives and portfolio focus as key contributors to the year on year increase in profitability.

The company also reported core earnings per share from continuing operations in Q2 2026 of approximately $1.80, compared with about $1.65 in Q2 2025 on a continuing operations basis. That equates to growth of roughly 9% year on year, showing that Novartis converted revenue growth into faster bottom line expansion. For investors, the core EPS trajectory remains central to how Novartis stock is valued, particularly given the group’s commitment to shareholder returns via dividends and buybacks.

Full year 2026 guidance and margin focus

Alongside the Q2 2026 numbers, Novartis maintained or slightly raised elements of its full year 2026 guidance. In its 16 July 2026 investor communication, the company guided to mid single digit net sales growth for 2026 at constant currencies, broadly consistent with the Q2 2026 progression. That outlook compares with low single digit growth achieved in 2025, signaling an ambition to accelerate top line momentum as recently launched medicines gain scale.

In terms of profitability, Novartis indicated that core operating income for full year 2026 is expected to grow in the high single digit to low double digit percentage range compared with 2025. This implies a step up from the roughly high single digit core operating income growth delivered in full year 2025, underscoring management’s focus on margin expansion. The combination of productivity measures, mix improvement toward specialty medicines and disciplined capital allocation is intended to support this higher growth range in 2026.

Novartis also reiterated its capital returns framework, including a progressive dividend and continued share repurchases. According to its most recent annual report for fiscal 2025, Novartis proposed a dividend of CHF 3.40 per share for 2025, up from CHF 3.30 for 2024, an increase of about 3%. That dividend growth, together with earnings expansion, is a key factor for income-oriented investors assessing Novartis stock, even as near term performance depends heavily on clinical and regulatory milestones.

Cosentyx drives immunology growth

Novartis’ product portfolio is anchored by several blockbuster therapies, and Cosentyx is a central pillar in its immunology franchise. Cosentyx, a monoclonal antibody targeting IL 17 for conditions such as psoriasis and ankylosing spondylitis, has become one of Novartis’ largest revenue contributors. According to recent company data for fiscal 2025, Cosentyx generated around $5.0 billion in annual sales, up from approximately $4.7 billion in 2024, representing growth of roughly 6%. This expansion reflects broader indications and geographic penetration, including newer launches in pediatric and axial spondyloarthritis segments.

The Q2 2026 results presentation highlighted continued double digit volume growth for Cosentyx in several key markets, even as pricing pressure and competition in immunology remain intense. Novartis indicated that Cosentyx maintained strong share positions in the moderate to severe plaque psoriasis market, aided by long term safety and efficacy data. For investors, the sustainability of Cosentyx growth is closely watched, since it underpins part of the company’s guidance for mid single digit net sales growth in 2026 and contributes materially to core operating income.

Beyond Cosentyx, Novartis is pushing other innovative immunology assets, including treatments for hidradenitis suppurativa and psoriatic arthritis. The company has emphasized in its investor materials that expanding indications for existing products and accelerating launches of new biologics and small molecules should help offset generic erosion in more mature parts of the portfolio. Pipeline readouts in immunology during late 2026 and 2027 are therefore likely to be key catalysts for Novartis stock.

Novartis stock trades steadily on SIX

On SIX Swiss Exchange, Novartis stock trades under the primary listing in Swiss francs. As of 16 July 2026, shortly after the Q2 2026 earnings release, Novartis shares closed around CHF 94 per share, compared with roughly CHF 88 at the start of 2026. That equates to a year to date gain of about 7%, broadly in line with or slightly ahead of major European pharmaceuticals peers over the same period, according to market data from leading Swiss equity portals.

Over the past twelve months through mid July 2026, Novartis stock has traded in an approximate range between CHF 82 and CHF 98. The recent level near CHF 94 places the shares closer to the upper part of this 52 week band, indicating that the market has priced in both the Q2 2026 earnings beat and the more confident full year 2026 margin guidance. For investors, the proximity to the recent high raises questions about upside potential relative to regulatory and clinical risks in the pipeline, but also reflects perceived defensive qualities of large cap pharmaceuticals in a mixed macroeconomic environment.

Based on Novartis’ share price around CHF 94 and shares outstanding cited in its latest annual report for fiscal 2025, the company’s market capitalization stands in the region of CHF 200 billion as of mid July 2026. That size makes Novartis one of Europe’s largest healthcare companies and a core constituent of Swiss and European equity indices. Novartis’ scale also underpins its ability to fund extensive research and development while maintaining shareholder distributions, a balance that shapes how Novartis stock is positioned in diversified portfolios.